CYP2D6 phenotype and the metabolism of nicotine and cotinine

被引：23
|
作者：
Benowitz, NL
Jacob, P
PerezStable, E
机构：
[1] UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA
[2] UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA
来源：
PHARMACOGENETICS | 1996年 / 6卷 / 03期
关键词：
nicotine; cotinine; metabolism; CYP2D6;
D O I：
10.1097/00008571-199606000-00006
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
That CYP2D6 activity is an important determinant of nicotine metabolism and that people who have abnormal CYP2D6 genes are poor metabolizers of nicotine has been reported in the medical literature. The aim of this study was to assess the role of CYP2D6 in nicotine metabolism, Specifically, we compared the clearance of stable isotope-labelled nicotine and cotinine in 11 poor and 33 extensive metabolizers of dextromethorphan, a probe for CYP2D6 activity, The groups were matched by gender, age and ethnicity, Nicotine and cotinine kinetics were quite similar for cases and controls, These data suggest that CYP2D6 is nob a major isozyme for the metabolism of nicotine or cotinine.
引用
收藏
页码：239 / 242
页数：4
相关论文
共 50 条
  • [31] Correlation between cytochrome P-450CYP2D6 CYP2D6) genotype and phenotype
    Chen, SQ
    Wedlund, PJ
    ACTA PHARMACOLOGICA SINICA, 1999, 20 (07): : 585 - 588
  • [32] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [33] Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol
    Fang, J
    Baker, GB
    Silverstone, PH
    Coutts, RT
    CELLULAR AND MOLECULAR NEUROBIOLOGY, 1997, 17 (02) : 227 - 233
  • [34] Involvement of CYP3A4 and CYP2D6 in the Metabolism of Haloperidol
    Jian Fang
    Glen B. Baker
    Peter H. Silverstone
    Ronald T. Coutts
    Cellular and Molecular Neurobiology, 1997, 17 : 227 - 233
  • [35] Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6
    Livezey, Mara R.
    Briggs, Erran D.
    Bolles, Amanda K.
    Nagy, Leslie D.
    Fujiwara, Rina
    Furge, Laura Lowe
    XENOBIOTICA, 2014, 44 (04) : 309 - 319
  • [36] Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR
    Hersberger, M
    Marti-Jaun, J
    Rentsch, K
    Hänseler, E
    CLINICAL CHEMISTRY, 2000, 46 (08) : 1072 - 1077
  • [37] The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype
    Ayman Al-Shurbaji
    Juliette Säwe
    European Journal of Clinical Pharmacology, 2002, 57 : 877 - 881
  • [38] The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype
    Al-Shurbaji, A
    Säwe, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 57 (12) : 877 - 881
  • [39] Decreased capacity for debrisoquine metabolism among black Tanzanians:: analyses of the CYP2D6 genotype and phenotype
    Wennerholm, A
    Johansson, I
    Massele, AY
    Jande, M
    Alm, C
    Aden-Abdi, Y
    Dahl, ML
    Ingelman-Sundberg, M
    Bertilsson, L
    Gustafsson, LL
    PHARMACOGENETICS, 1999, 9 (06): : 707 - 714
  • [40] CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance
    Higgins, Michaela J.
    Stearns, Vered
    CURRENT ONCOLOGY REPORTS, 2010, 12 (01) : 7 - 15
12345